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life criteria or even QoL impact on family. ConClusions: This analysis presented 
a possible scenario for the implementation of VBA. None of the drugs with a nega-
tive recommendation would get a positive recommendation under this scenario. 
The products at most risk are those currently accepted using end-of-life criteria. 
However, how the new value elements will be weighted has yet to be determined.
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objeCtives: To characterise country-level changes to international reference 
pricing (IRP) policy frameworks across 39 markets, and understand how coun-
tries amend this tool. Methods: Qualitative interviews were conducted with 50 
stakeholders across 39 markets, representing 37 payers or payer influencers and 13 
industry stakeholders. These interviews focused on country-level IRP methodology, 
both past and present. Extensive secondary research of government websites and 
existing literature was also conducted. A qualitative and semi-quantitative analysis 
of these findings was undertaken to identify key trends in how IRP has been modi-
fied as a policy tool since implementation. Results: Of the markets considered, 
IRP has remained comparatively stable – in terms of both the countries comprising 
the reference basket and the underlying formula for determining the reference price 
remaining unchanged – in just under one-third of the 39 markets. In contrast, just 
over one-third of these markets have modified their IRP baskets to include one or 
more additional countries with the objective of lowering prices. A smaller number 
have made substantive changes to the IRP formula itself, notably with four markets 
transitioning from taking the average price of their basket as a reference to either 
taking the average of the three lowest or taking the lowest. ConClusions: IRP 
serves as a dynamic policy tool, changing to reflect individual country circum-
stances and broader policy reform over time. While a number of markets have 
maintained a stable IRP regime since inception, a larger number have made some 
changes, the most common being to add one or more markets to the reference 
basket. Although changes to IRP are mostly concentrated in Eastern European mar-
kets, as well as Western European markets most impacted by the recent economic 
crisis, the present study also suggests that there is considerable variation across 
geographies and time in how countries adapt their use of IRP.
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objeCtives: NICE’s guides to the process of Multiple Technology Appraisals (MTA) 
and Single Technology Appraisals (STA) provide a valuable source of information 
to enable stakeholders to engage in Health Technology Appraisals (HTAs). NICE 
recently conducted a review of the process guides which has implications for all 
stakeholders involved with MTAs and STAs. The objective of this analysis was to 
identify the number and type of amendments within the guides in order to high-
light the most important changes for consultees and commentators. Methods: 
Narrative synthesis was used to systematically identify, classify and explore the 
impact of the proposed amendments to the MTA and STA process guides. The 
hypothesis was that the amalgamation of the MTA and STA guides would simplify 
both TA processes whilst increasing rigour and transparency. Sources of reference 
were the draft of the new process guide, the NICE Senior Management Team Board 
Cover Paper, and the 2009 MTA and STA process guides. Results: Amendments 
were classified as relating to the process itself (26%), data and confidential infor-
mation (44%), terminology (7%), and others (22%). Of the 27 amendments to the 
MTA and STA process guides, 4 (15%) were identified as major amendments which 
warrant specific appreciation. Major amendments included: (1) the STA decision 
problem meeting moving to after the Department of Health referral; (2) stricter rules 
around the marking of confidential information; (3) full publication of MTAs; and 
(4) MTAs now have the opportunity to go straight to Final Appraisal Determination 
(FAD) following the first committee meeting. ConClusions: The draft process 
guide suggests that the new MTA and STA processes will foster greater engage-
ment between stakeholders early on, increase transparency, and enable patients 
to have quicker access to innovative medicines which are able to go straight to FAD.
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objeCtives: In Germany, an early assessment of benefit (EAB) is required for new 
medicines since January 2011. The pharmaceutical manufacturer submits a dossier 
on additional benefit over comparative treatment which is subsequently evaluated 
by the Institute for Quality and Efficiency in Health Care (IQWiG). Stakeholders can 
comment on the evaluation in a formal comments procedure. The final decision 
on additional benefit is made by the Federal Joint Committee (G-BA); it provides the 
basis for price negotiations between manufacturer and statutory health insurance 
funds. Quality of life (QoL) is one of four criteria for benefit evaluation. This qualita-
tive study aimed to determine methodological requirements for QoL measurement 
in the German EAB. Methods: A qualitative content analysis according to Mayring 
was conducted. Documents of all EABs completed until December 2013 (including 
dossier, IQWiG evaluation, protocol of the oral hearing, and G-BA decision) were 
searched for the term QoL or synonyms. Relevant passages were extracted and 
reduced to key content by two researchers independently. On the basis of subse-
quent consensus building, recurring themes of the term’s usage in the EAB process 
were identified. Results: In the 66 early assessments of benefit included in the 
analysis, a range of methodological requirements regarding QoL assessment, analy-
sis, and interpretation emerged. Dominant topics included: the appropriate level of 
disease-specificity of QoL instruments; required evidence on an instrument’s valid-
ity and on the validity of a minimal important difference; appropriate duration of 
QoL assessment; consequences of potential bias due to unblinded study design or 
missing data; interpretation of results that differed between subscales of an instru-
ment; non-acceptance of surrogate endpoints for QoL. ConClusions: Evidence 
on QoL can have high impact on the additional benefit determined by the G-BA. 
Therefore, QoL assessment and analysis in clinical studies that shall enter benefit 
dossiers should confirm with a range of methodological requirements.
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objeCtives: New health technologies are required to demonstrate both clinical and 
cost-effectiveness before recommendation by the National Institute for Health and 
Care Excellence (NICE) for reimbursement in England; however, a large proportion 
of submissions are rejected due to non-robust economic analysis. Published NICE 
guidance includes a comprehensive critique of submitted economic evidence so, to 
help inform future submissions, we assessed the flaws in cost-effectiveness models 
leading to rejection by NICE. Methods: All NICE single technology appraisals from 
January 2006 to May 2014 were included in the analysis. Multiple technology apprais-
als, resubmissions, vaccination programmes, requests for advice, and submissions 
where an incremental cost-effectiveness ratio (ICER) could not be determined were 
excluded. Recommendations and reasoning across decisions were extracted, with 
a focus on the critique of the economic evidence. Results: 121 NICE submissions 
met the inclusion criteria, 28 (19.8%) of which were rejected. Non-robust economic 
analysis was one of the listed reasons for rejection in 75.0% (21) of cases, and in all 
cases where the submitted ICER was below the £30,000 cost-effectiveness thresh-
old. Within these submissions, the key drivers behind rejection due to non-robust 
cost-effectiveness modelling were: a high level of uncertainty in inputs (leading to a 
sensitive or unreliable ICER) (in 90.5% of cases); mishandling of data (e.g., overstated 
treatment effect or failure to account for adverse events) (85.7%); misalignment to 
the reference case (e.g., inappropriate comparator or weak methodology) (38.1%); 
and unrealistic assumptions (38.1%). ConClusions: Non-robust economic analysis 
is one of the main reasons behind rejection of NICE submissions, largely due to high 
uncertainty, or selective use of data to favor the health technology being appraised. 
Early modelling may allow manufacturers to identify and address sources of uncer-
tainty or weakness early in the clinical development process, in order to construct 
a convincing and robust economic argument ahead of reimbursement submission.
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objeCtives: As of 1st January 2011 the German drug market is regulated by the 
act of the reorganization of the pharmaceutical market (AMNOG). Since then the 
normal procedure for reimbursement of a new pharmaceutical is an early benefit 
assessment by the joint federal committee (G-BA) which determines one of six 
additional benefit levels. According to AMNOG any specification of the reimburse-
ment price shall be based on the outcomes of the early benefit assessment. Hence 
this assessment takes a key role for market access of a new drug in Germany which 
poses the question whether it is possible to predict the level of additional benefit 
that will be established by the G-BA. Methods: In order to evaluate a possible 
predictor of G-BA decisions, the ‘evaluation of pharmaceutical innovations (EVITA)’ 
score was calculated and retrospectively compared with 40 published G-BA deci-
sions. The EVITA algorithm evaluates a new compound for a given indication and in 
relation to a relevant comparator on the basis of randomized controlled trial (RCT) 
evidence. EVITA translates the RCT outcomes on the therapeutic benefit and risk 
profile into rating points, which are expressed as a total EVITA score. Results: 
Univariate ordinary least squares and ordered logit regression analyses show sta-
tistically significant correlations between EVITA scores and the G-BA additional 
benefit levels. Moreover, for the prediction of an additional benefit level of at least 
‘minor’, an EVITA score cutpoint of ≥ 3 is associated with a sensitivity of 100% and 
a specificity of 80%. For the prediction of an additional benefit level of at least ‘con-
siderable’, an EVITA score cutpoint of ≥ 7.5 is associated with a sensitivity of 100% 
and a specificity of 93.1%. ConClusions:  The present investigation indicates that 
the EVITA score may have the potential for the prediction of G-BA decisions related 
to AMNOG early benefit assessments.
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objeCtives: The National Institute for Health and Care Excellence (NICE) under-
takes appraisals of selected health technologies, and those judged to be cost-
effective must be funded for use on the National Health Service in England and 
Wales. Obtaining a positive appraisal decision is therefore important to commer-
cial developers seeking market access, who require consistent application of topic 
selection criteria (which were amended in 2009). We sought to establish which 
characteristics of drugs or their indications were most important in the decision 
to undertake an appraisal. Methods: All marketing authorisations (MAs) granted 
